文献速递炎症性肠病

粪菌移植联合贝洛托珠单抗治疗炎症性肠病合并复发性艰难梭菌感染的结局

Outcomes After Fecal Microbiota Transplantation in Combination With Bezlotoxumab for Inflammatory Bowel Disease and Recurrent Clostridioides difficile Infection.
PubMed 文献 · Am J Gastroenterol · 2024-03-19

本研究为多中心随机安慰剂对照试验,纳入61例炎症性肠病合并复发性艰难梭菌感染患者,所有患者接受单次结肠镜粪菌移植,并1:1随机接受贝洛托珠单抗或安慰剂。总体5例(8%)出现艰难梭菌感染复发,治疗组4例、安慰剂组1例(13% vs 3%,P=0.15),联合方案较单用粪菌移植未见明确获益。

要点

  • 炎症性肠病合并复发性艰难梭菌感染患者中,贝洛托珠单抗联合粪菌移植较单用粪菌移植未见明确获益。
  • 治疗组艰难梭菌感染复发4例(13%),安慰剂组1例(3%),差异未达统计学显著(P=0.15)。
  • 总体复发5例(8%),两组比较需更大样本验证。

核心结论

  • 在炎症性肠病合并复发性艰难梭菌感染患者中,粪菌移植联合贝洛托珠单抗较单用粪菌移植未见明确获益。

研究设计与样本

  • 多中心随机安慰剂对照试验,所有患者接受单次结肠镜粪菌移植,并1:1随机接受贝洛托珠单抗或安慰剂。
  • 共纳入61例患者,其中治疗组30例、安慰剂组31例。

主要发现

  • 总体5例(8%)出现艰难梭菌感染复发,治疗组4例(13%)vs 安慰剂组1例(3%),P=0.15。
  • 联合方案较单用粪菌移植未见明确获益。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fecal microbiota transplantation (FMT) prevents recurrent Clostridioides difficile infections (rCDI) in patients with inflammatory bowel disease. Bezlotoxumab is also indicated to prevent rCDI. We assess the impact of FMT in combination with bezlotoxumab in patients with inflammatory bowel disease and rCDI. We conducted a multicenter randomized placebo-controlled trial. All received a single colonoscopic FMT. Patients were randomized 1:1 to receive bezlotoxumab or placebo. Sixty-one patients were enrolled (30 received treatment and 31 received placebo). Overall, 5 participants (8%) experienced a CDI recurrence; 4 in the treatment arm, 1 in the placebo arm (13% vs 3%, P = 0.15). There was no clear benefit to the combination approach compared with FMT alone.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Allegretti JR, Axelrad J, Dalal RS, et al. Outcomes After Fecal Microbiota Transplantation in Combination With Bezlotoxumab for Inflammatory Bowel Disease and Recurrent Clostridioides difficile Infection. Am J Gastroenterol. 2024. PMID: 38501667. doi:10.14309/ajg.0000000000002770

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。